Antiinflammatory activity of melatonin in central nervous system

Current Neuropharmacology

Volumn 8, Issue 3, 2010, Pages 228-242

  Esposito, Emanuela ^a   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Antioxidant; Free radical; Inflammation; Melatonin; Mitochondria; Neurodegeneration

Indexed keywords

MATRIX METALLOPROTEINASE; MELATONIN; MELATONIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUNTINGTON CHOREA; IMMUNOMODULATION; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

EID: 78549282095     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015910792246155     Document Type: Article

References (225)

1. Agez, L.; Laurent, V.; Guerrero, H.Y.; Pévet, P.; Masson-Pévet, M.; Gauer, F. Endogenous melatonin provides an effective circadian message to both the suprachiasmatic nuclei and the pars tuberalis of the rat. J. Pineal Res., 2009, 46(1), 95-105.
2. Altun, A.; Ugur-Altun, B. Melatonin: therapeutic and clinical utilization. Int. J. Clin. Pract., 2007, 61, 835-845.
3. Anderson, A.J. Mechanisms and pathways of inflammatory responses in CNS trauma: spinal cord injury. J. Spinal Cord. Med., 2002, 25, 70-79.
4. Anderson, D.K.; Hall, E.D. Pathophysiology of spinal cord trauma. Ann. Emerg. Med., 1993, 22, 987-992.
5. Andrabi, S.A.; Sayeed, I.; Siemen, D.; Wolf, G.; Horn, T.F. Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J., 2004, 18, 869-871.
6. Antolin, I.; Rodriguez, C.; Sain, R.M.; Uría, H.; Kotler, M.L.; Rodríguez-Colunga, M.J.; Tolivia, D.; Menéndez-Peláez, A. Neurohormone melatonin prevents damage: effect on gene expression for antioxidative enzymes. FASEB J., 1996, 10, 882-890.
7. Ates, O.; Cayli, S.; Gurses, I.; Yucel, N.; Altinoz, E.; Iraz, M.; Kocak, A.; Yologlu, S. Does pinealectomy affect the recovery rate after spinal cord injury? Neurol. Res., 2007, 29, 533-539.
8. Barnes, P.J.; Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 1997, 336, 1066-1071.
9. Bar-Peled, O.; Knudson, M.; Korsmeyer, S.J.; Rothstein, J.D. Motor neuron degeneration is attenuated in Bax-deficient neurons in vitro. J. Neurosci. Res., 1999, 55, 542-556.
10. Beattie, M.S. Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol. Med., 2004, 10, 580-583.
11. Beattie, M.S.; Farooqui, A.A.; Bresnahan, J.C. Review of current evidence for apoptosis after spinal cord injury. J. Neurotrauma, 2000, 17, 915-925.
12. Becker-Andre, M.; Wiesenberg, I.; Schaeren-Wiemers, N.; Andre, E.; Missbach, M.; Saurat, J.H.; Carlberg, C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem., 1994, 269(46), 28531-28534.
13. Benitez-King, G.; Anton-Tay, F. Calmodulin mediates melatonin cytoskeletal effects. Experientia., 1993, 49, 635-641.
14. Bethea, J.R.; Dietrich, W.D. Targeting the host inflammatory response in traumatic spinal cord injury. Curr. Opin. Neurol., 2002, 15, 355-360.
15. Bilici, D.; Akpinar, E.; Kiziltunç, A. Protective effect of melatonin in carrageenan-induced acute local inflammation. Pharmacol. Res., 2002, 46(2), 133-9.
16. Bogaerts, V.; Theuns, J.; van Broeckhoven, C. Genetic finding in Parkinson's disease and translation into treatment: a loading role for mitochondria? Genes Brain Behav., 2008, 7, 129-151.
17. Bolanos, J.P.; Almeida, A.; Stewart, V.; Peuchen, S.; Land, J.M.; Clark, J.B.; Heales, S.J. Nitric oxidemediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem., 1997, 68, 2227-2240.
18. Bond, W.S. Toxic reactions and side effects of glucocorticoids in man. Am. J. Hosp. Pharm., 1977, 34, 479-485.
19. Borlongan, C.V.; Su, T.P.; Wang, Y. Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons. Neuroreport, 2000, 11, 923-926.
20. Brinckerho, C.E.; Matrisian, L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell. Biol., 2002, 3, 207-214.
21. Caballero, B.; Vega-Naredo, I.; Sierra, V.; Huidobro-Fernandez, C.; Soria-Valles, C.; De Gonzalo-Calvo, D.; Tolivia, D.; Pallas, M.; Camins, A.; Rodriguez-Colunga, M.J.; Coto-Montes, A. Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence accelerated mice. J. Pineal Res., 2009, 46, 106-114.
22. Calabrese, V.; Boyd-Kimball, D.; Scapagnini, G.; Butterfield, D.A. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo 2004, 18, 245-268.
23. Calabrese, V.; Scapagnini, G.; Giuffrida Stella, A.M.; Bates, T.E.; Clark, J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res., 2001, 26, 739-764.
24. Camello-Almaraz, C.; Gomez-Pinilla, P.J.; Pozo, M.J.; Camello, P.J. Age-related alterations in Ca2+signals and mitochondrial membrane potential in exocrine cells are prevented by melatonin. J. Pineal Res., 2008, 45, 191-198.
25. Carlson, G.D.; Gorden, C. Current developments in spinal cord injury research. Spine J., 2002, 2, 116-128.
26. Carrillo-Vico, A.; Lardone, P.J.; Fernandez-Santos, J.M.; Martín-Lacave, I.; Calvo, J.R.; Karasek, M.; Guerrero, J.M. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin 2/ interleukin 2 receptor system. J. Clin. Endocrinol. Metab., 2005, 90, 992-1000.
27. Carrillo-Vico, A.; Lardone, P.J.; Naji, L.; Fernández-Santos, J.M.; Martín-Lacave, I.; Guerrero, J.M.; Calvo, J.R. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and antiapoptotic effects. J. Pineal Res., 2005, 39, 400-408.
28. Casha, S.; Yu, W.R.; Fehlings, M.G. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience, 2001, 103, 203-218.
29. Cayli, S.R.; Kocak, A.; Yilmaz, U.; Tekiner, A.; Erbil, M.; Ozturk, C.; Batcioglu, K.; Yologlu, S. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury. Eur. Spine J., 2004, 13, 724-732.
30. Cervantes, M.; Morali, G.; Letechipia-Vallejo, G. Melatonin and ischemia-reperfusion injury of the brain. J. Pineal Res., 2008, 45, 1-7.
31. Chatham, W.W.; Swaim, R.; Frohsin, H.; Heck, L.W.; Miller, E.J.; Blackburn, W.D. Jr. Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum., 1993, 36, 51-58.
32. Chattoraj, A.; Liu, T.; Zhang, L.S.; Huang, Z.; Borjigin, J. Melatonin formation in mammals: in vivo perspectives. Rev. Endocr. Metab. Disord., 2009, 10(4), 237-43.
33. Cheung, R.T.; Tipoe, G.L.; Tam, S.; Ma, E.S.; Zou, L.Y.; Chan, P.S. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J. Pineal Res., 2006, 41(4), 337-43.
34. Chittenden, T.; Harrington, E.A.; O'connor, R.; Flemington, C.; Lutz, R.J.; Evan, G.I.; Guild, B.C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature, 1995, 374, 733-736.
35. Chung, S.Y.; Han, S.H. Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J. Pineal Res., 2003, 34, 95-102.
36. Costa, E.J.; Shida, C.S.; Biaggi, M.H.; Ito, A.S.; Lamy-Freund, M.T. How melatonin interacts with lipid bilayer: a study by fluorescence and ESR spectroscopies. FEBS Lett., 1997, 416, 103-106.
37. Costantino, G.; Cuzzocrea, S.; Mazzon, E.; Caputi, A.P. Protective effects of melatonin in zymosan-activated plasma-induced paw inflammation. Eur. J. Pharmacol., 1998, 363(1), 57-63.
38. Crespo, E.; Macias, M.; Pozo, D.; Escames, G.; Martin, M.; Vives, F.; Guerrero, J.M.; Acuna-Castroviejo, D. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J., 1999, 13, 1537-1546.
39. Cuzzocrea, S.; Riley, D.P.; Caputi, A.P.; Salvemini, D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev., 2001, 53, 135-159.
40. Cuzzocrea, S.; Zingarelli, B.; Gilad, E.; Hake, P.; Salzman, A.L.; Szabó, C. Protective effect of melatonin in carrageenan-induced models of local inflammation: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J. Pineal Res., 1997, 23(2), 106-116.
41. Dawson, V.L.; Dawson, T.M. Nitric oxide neurotoxicity. J. Chem. Neuroanat., 1996, 10, 183-201.
42. Seabra, V.; Bignotto, M.; Pinto, L.R. Jr; Tufik, S. Randomised double blind clinical trial, controlled with placebo of the toxicology of chronic melatonin treatment. J. Pineal Res., 2000, 29, 193-200.
43. Deng, Y.Q.; Xu, G.G.; Duan, P.; Zhang, Q.; Wang, J.Z. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol. Sin., 2005, 26, 519-526.
44. Droge, W. Oxidative stress and aging. Adv. Exp. Med. Biol., 2003, 543,191-200.
45. Duchossoy, Y.; Arnaud, S.; Feldblum, S. Matrix metalloproteinases: potential therapeutic target in spinal cord injury. Clin. Chem. Lab. Med., 2001, 39, 362-367.
46. Eddleston, M.; Mucke, L. Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience, 1993, 54, 5-36.
47. Emerit, J.; Edeas, M.; Bricaire, F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother., 2004, 58, 39-46.
48. Endoh, M.; Maiese, K.; Wagner, J. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global oxygen and glucose deprivation. Brain Res., 1994, 651, 92-100.
49. Escames, G.; Leon, J.; Macias, M.; Khaldy, H.; Acuna-Castroviejo, D. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J., 2003, 17, 932-934.
50. Esposito, E.; Genovese, T.; Caminiti, R.; Bramanti, P.; Meli, R.; Cuzzocrea, S. Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J. Pineal Res., 2009, 46, 79-86.
51. Esposito, E.; Genovese, T.; Caminiti, R.; Bramanti, P.; Meli, R.; Cuzzocrea, S. Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury. J. Pineal Res., 2008, 45, 149-156.
52. Feng, Z.; Chang, Y.; Cheng, Y.; Zhang, B.L.; Qu, Z.W.; Qin, C.; Zhang, J.T. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal Res., 2004, 37, 129-136.
53. Feng, Z.; Cheng, Y.; Zhang, J.T. Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J. Pineal Res., 2004, 37, 198-206.
54. Feng, Z.; Qin, C.; Chang, Y.; Zhang, J.T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med., 2006, 40, 101-109.
55. Feng, Z.; Zhang, J.T. Protective effect of melatonin on betaamyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic. Biol. Med., 2004, 37, 1790-1801.
56. Floyd, R.A.; Carney, J.M. The role of metal ions in oxidative processes and aging. Toxicol. Ind. Health, 1993, 9, 197-214.
57. Floyd, R.A.; Hensley, K. Oxidative stress in braing aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging, 2002, 23, 795-807.
58. Fu, X.; Kassim, S.Y.; Parks, W.C.; Heinecke, J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem., 2001, 276, 41279-41287.
59. Fujimoto, T.; Nakamura, T.; Ikeda, T.; Takagi, K. Potent protective effects of melatonin on experimental spinal cord injury. Spine, 2000, 25, 769-775.
60. Garcia, J.J.; Reiter, R.J.; Pie, J.; Ortiz, G.G.; Cabrera, J.; Sáinz, R.M.; Acuña-Castroviejo, D. Role of pinoline and melatonin in stabilizing hepatic microsomal membranes against oxidative stress. J. Bioenerg. Biomembr., 1999, 31, 609-616.
61. Garcia-Navarro, A.; Gonzalez-Puga, C.; Escames, G.; López, L.C.; López, A.; López-Cantarero, M.; Camacho, E.; Espinosa, A.; Gallo, M.A.; Acuña-Castroviejo, D. Cellular mechanisms envolved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J. Pineal Res., 2007, 43, 195-205.
62. Gegg, M.E.; Beltran, B.; Salas-Pino, S.; Bolanos, J.P.; Clark, J.B.; Moncada, S.; Heales, S.J. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/ neurodegeneration? J. Neurochem., 2002, 86, 228-237.
63. Genovese, T.; Mazzon, E.; Crisafulli, C.; Esposito, E.; Di Paola, R.; Muià, C.; Di Bella, P.; Bramanti, P.; Cuzzocrea, S. Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. J. Pineal Res., 2007, 43, 140-153.
64. Genovese, T.; Mazzon, E.; Mariotto, S.; Menegazzi, M.; Cardali, S.; Conti, A.; Suzuki, H.; Bramanti, P.; Cuzzocrea, S. Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury. J. Neurosurg. Spine, 2006, 4, 145-153.
65. Genovese, T.; Mazzon, E.; Muia, C.; Bramanti, P.; De Sarro, A.; Cuzzocrea, S. Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J. Pineal Res., 2005, 38, 198-208.
66. Gilad, E.; Wong, H.R.; Zingarelli, B.; Virág, L., O'Connor, M.; Salzman, A.L.; Szabó, C. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF-kB activation. FASEB J., 1998, 12, 685-693.
67. Gitto, E.; Reiter, R.J.; Sabatino, G.; Buonocore, G.; Romeo, C.; Gitto, P.; Buggé, C.; Trimarchi, G.; Barberi, I. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J. Pineal Res., 2005, 39, 287-293.
68. Guenther, A.L.; Schmidt, S.L.; Laatsch, H.; Fotso, S.; Ness, H.; Ressmeyer, A.R.; Poeggeler, B.; Hardeland, R. Reactions of the melatonin metabolite AMK (N1-acetyl-5-methxykynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J. Pineal Res., 2005, 39, 251-260.
69. Guinjoan, S.M.; Vigo, D.E.; Castro, M.N.; Tateosian, N.; Chuluyan, E.; Costanzo, E.; Fahrer, R.; Grancelli, H.; Leiguarda, R.; Cardinali, D.P. Mood, Th1/Th2 cytokine profile, and autonomic activity in older adults with acute/decompensated Herat failure: preliminary observations. World J. Biol. Psychiatry., 2008, 20, 1-6.
70. Gul, S.; Celik, S.E.; Kalayci, M.; Taşyürekli, M.; Cokar, N.; Bilge, T. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. Surg. Neurol., 2005, 64, 355-361.
71. Gutierrez-Cuesta, J.; Tajes, M.; Jimenez, A.; Coto-Montes, A.; Camins, A.; Pallas, M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J. Pineal Res., 2008, 45, 497-505.
72. Hagan, R.M.; Oakley, N.R. Melatonin comes of age? Trends Pharmacol. Sci., 1995, 16, 81-83.
73. Hardeland, R.; Backhaus, C.; Fadavi, A. Reactions of the NO redox forms BO+, *NO and HNO (protonated NO-) with the melatonin metabolite B1-acetyl-5-methoxykynurenamine. J. Pineal Res., 2007, 43, 382-388.
74. Harlan, J.M. Consequences of leukocytes-vessel wall interactions in inflammatory and immune reactions. Semin. Thromb. Hemost., 1987, 13, 425-433.
75. Hausmann, O.N. Post-traumatic inflammation following spinal cord injury. Spinal Cord., 2003, 41, 369-378.
76. Hill, J.M.; Switzer, R.C. The regional distribution and cellular localization of iron in rat brain. Neuroscience, 1984, 11, 595-603.
77. Hirata, F.; Hayaishi, O.; Tokuyama, T.; Seno, S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem., 1974, 249, 1311-1313.
78. Hsu, J.Y.; Mckeon, R.; Goussev, S.; Werb, Z., Lee, J.U.; Trivedi, A.; Noble-Haeusslein, L.J. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J. Neurosci., 2006, 26, 9841-9850.
79. Huerto-Delgadillo, L.; Anton-Tay, F.; Benitez-King, G. Effects of melatonin on microtubule assembly depend on hormone concentration: role of melatonin as a calmodulin antagonist. J. Pineal Res., 1994, 17, 55-62.
80. Iacovitti, L.; Stull, N.D.; Johnston, K. Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res., 1997, 768, 317-326.
81. Iacovitti, L.; Stull, N.D.; Mishizen, A. Neurotransmitters, KCl and antioxidants rescue striatal neurons from apoptotic cell death in culture. Brain Res., 1999, 816, 276-285.
82. Jacob, S.; Poeggeler, B.; Weishaupt, J.H.; Siren, A.L.; Hardeland, R.; Bahr, M.; Ehrenreich, H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): High tolerability of daily oral melatonin administration in ALS patients. J. Pineal Res., 2002, 33, 186-187.
83. Jahnke, G.; Marr, M.; Myers, C.; Wilson, R.; Travlos, G.; Price, C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol. Res., 1999, 50, 271-274.
84. Jan, J.E.; Hamilton, D.; Seward, N.; Fast, D.K.; Freeman, R.D.; Laudon, M. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J. Pineal Res., 2000, 29, 34-49.
85. Jang, M.H.; Jung, S.B.; Lee, M.H.; Kim, C.J.; Oh, Y.T.; Kang, I.; Kim, J.; Kim, E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett., 2005, 380, 26-31.
86. Jesudason, E.P.; Baben, B.; Ashok, B.S.; Masilamoni, J.G.; Kirubagaran, R.; Jebaraj, W.C.; Jayakumar, R. Anti-inflammatory effect of melatonin on a beta vaccination in mice. Mol. Cell. Biochem., 2007, 298, 69-81.
87. Jockers, R.; Maurice, P.; Boutin, J.A.; Delagrange, P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br. J. Pharmacol., 2008, 154, 1182-1195.
88. Joo, J.Y.; Uz, T.; Manev, H. Opposite effects of pinealectomy and melatonin administration on brain damage following cerebral focal ischemia in rat. Restor. Neurol. Neurosci., 1998, 13, 185-191.
89. Jou, M.J.; Peng, T.I.; Reiter, R.J.; Jou, S.B.; Wu, H.Y.; Wen, S.T. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal Res., 2004, 37, 55-70.
90. Jou, M.J.; Peng, T.I.; Yu, P.Z.; Jou, S.B.; Reiter, R.J.; Chen, J.Y.; Wu, H.Y.; Chen, C.C.; Hsu, L.F. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J. Pineal Res., 2007, 43, 389-403.
91. Kaptanoglu, E.; Tuncel, M.; Palaoglu, S.; Konan, A.; Demirpençe, E.; Kilinç, K. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury. J. Neurosurg., 2000, 93, 77-84.
92. Kilic, E.; Kilic, U.; Yulug, B.; Hermann, D.M.; Reiter, R.J. Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J. Pineal Res., 2004, 36, 171-176.
93. Kilic, U.; Kilic, E.; Reiter, R.J.; Bassetti, C.L.; Hermann, D.M. Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J. Pineal Res., 2005, 38, 67-71.
94. Kirwan, J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Lowdose Glucocorticoid Study Group. N. Engl. J. Med., 1995, 333, 142-146.
95. Klusman, I.; Schwab, M.E. Effects of pro-inflammatory cytokines in experimental spinal cord injury. Brain Res., 1997, 762, 173-184.
96. Kneisley, L.W.; Moskowitz, M.A.; Lynch, H.G. Cervical spinal cord lesions disrupt the rhythm in human melatonin excretion. J. Neural. Transm. Suppl., 1978, 13, 311-323.
97. Koh, P.O. Melatonin attenuates the cerebral ischemic injury via the MEK/ERK/p90RSK/bad signaling cascade. J. Vet. Med. Sci., 2008, 70, 1219-1223.
98. Koh, P.O. Melatonin attenuates the focal cerebral ischemic injury by inhibiting the dissociation of pBad from 14-3-3. J. Pineal Res., 2008, 44, 101-106.
99. Korkmaz, A.; Reiter, R.J.; Topal, T.; Manchester, L.C.; Oter, S.; Tan, D.X. Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med., 2009, 15, 43-50.
100. Kostrzewa, R.M.; Segura-Aguilar, J. Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review. Neurotox. Res., 2003, 5, 375-383.
101. La Fleur, M.; Underwood, J.L.; Rappolee, D.A.; Werb, Z. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J. Exp. Med., 1996, 184, 2311-2326.
102. Leon, J.; Acuna-Castroviejo, D.; Escames, G.; Tan, D.X.; Reiter, R.J. Melatonin mitigates mitochondrial malfunction. J. Pineal Res., 2005, 38, 1-9.
103. Leon, J.; Escames, G.; Rodriguez, M.I.; Lopez, L.C.; Tapias, V.; Entrena, A.; Camacho, E.; Carrion, M.D.; Gallo, M.A.; Espinosa, A.; Tan, D.X.; Reiter, R.J.; Acuna-Castroviejo, D. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J. Neurochem., 2006, 98, 2023-2033.
104. Leonard, B.E.; Song, C. Stress and the immune system in the etiology of anxiety and depression. Pharmacol. Biochem. Behav., 1996, 54, 299-303.
105. Li, X.C.; Wang, Z.F.; Zhang, J.X.; Wang, Q.; Wang, J.Z. Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur. J. Pharmacol., 2005, 510, 25-30.
106. Li, Y., Jiang, D.H., Wang, M.L.; Jiao, D.R.; Pang, S.F. Rhythms of serum melatonin in patients with spinal lesions at the cervical, thoracic or lumbar region. Clin. Endocrinol., 1989, 30, 47-56.
107. Limson, J.; Nyokong, T.; Daya, S. The interaction of melatonin and its precursors with aluminum, cadmium, copper, iron, lead, and zinc: an absorptive voltammetry study. J. Pineal Res., 1998, 24, 15-21.
108. Lin, A.; Ho, L.T. Melatonin suppresses iron-induced neurodegeneration in rat brain. Free Radic. Biol. Med., 2000, 28, 904-911.
109. Lindsey, R.W.; Gugala, Z.; Pneumaticos, S.G. Injuries of the Vertebrae and Spinal Cord. In: "Trauma" 5th ed. Moore, E.E. Feliciano, D.V. Mattox, K.L. (Eds). McGraw Hill, 2003, pp. 459-492. (ISBN 0-07-137069-2).
110. Ling, X.; Zhang, L.M.; Lu, S.D.; Li, X.J.; Sun, F.Y. Protective effect of melatonin on injuried cerebral neurons is associated with bcl-2 protein over-expression. Zhongguo Yao Li. Xue Bao., 1999, 20, 409-414.
111. Liu, J.B.; Tang, T.S.; Yang, H.L.; Xiao, D.S. Antioxidation of melatonin against spinal cord injury in rats. Chin. Med J., 2004, 117, 571-575.
112. Liu, R.Y.; Zhou, J.N.; van Heerikhuize, J.; Hofman, M.A.; Swaab, D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein Eepsilon4/ 4 genotype. J. Clin. Endocrinol. Metab., 1999, 84, 323-327.
113. Liu, S.J.; Wang, J.Z. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol. Sin., 2002, 23, 183-187.
114. Lopez, A.; Garcia, J.A.; Escames, G.; Venegas, C.; Ortiz, F.; López, L.C.; Acuña-Castroviejo, D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J, Pineal Res., 2009, 46, 188-198.
115. Lu, B.; Wang, L.; Stehlik, C.; Medan, D.; Huang, C.; Hu, S.; Chen, F.; Shi, X.; Rojanasakul, Y. Phosphatidylinositol 3-kinase/ Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells. J. Immunol., 2006, 176, 6785-6793.
116. Mahlberg, R.; Walther, S.; Kalus, P.; Bohner, G.; Haedel, S.; Reischies, F.M.; Kuhl, K.P.; Hellweg, R.; Kunz, D. Pineal calcification in Alzheimer's disease: An in vivo study using computed tomography. Neurobiol. Aging., 2008, 29, 203-209.
117. Mailliet, F.; Ferry, G.; Vella, F.; Berger, S.; Cogé, F.; Chomarat, P.; Mallet, C.; Guénin, S.P.; Guillaumet, G.; Viaud-Massuard, M.C.; Yous, S.; Delagrange, P.; Boutin, J.A. Characterization of the melatoninergic MT3 binding site on the NRH: quinone oxidoreductase 2 enzyme. Biochem. Pharmacol., 2005, 71(1-2), 74-88.
118. Maldonado, M.D.; Murillo-Cabezas, F.; Terron, M.P.; Flores, L.J.; Tan, D.X.; Manchester, L.C.; Reiter, R.J. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J. Pineal Res., 2007, 42, 1-11.
119. Maldonado, M.D.; Siu, A.W.; Sanchez-Hidalgo, M. Melatonin and lipid uptake by murine fibroblasts: clinical implications. Neuroendocrinol. Lett., 2006, 27, 601-608.
120. Manda, K.; Ueno, M.; Anzai, K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J. Pineal Res. 2002, 42, 386-393.
121. Marchetti, B. Cross talk signals in the CNS: role for neurotrophic and hormonal factors, adhesion molecules and intercellular signalling agents in luteinizing hormone -releasing hormone (LHRH) -astroglial interactive network. Front Biosci., 1997, 5, d88-d125.
122. Martin, M.; Macias, M.; Escames, G.; Leon, J.; Acuna-Castroviejo, D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J., 2000, 14, 1677-1679.
123. Martin, V.; Sainz, R.M.; Antolin, I.; Mayo, J.C.; Herrera, F.; Rodríguez C. Several antioxidant pathways are involved in astrocyte protection by melatonin. J. Pineal Res., 2002, 33, 204-212.
124. Martinez, G.R.; Almeida, E.A.; Klitzke, C.F.; Onuki, J.; Prado, F.M.; Medeiros, M.H.; Di Mascio, P. Measurement of melatonin and its metabolites: importance for the evaluation of their biological roles. Endocrine, 2005, 27, 111-118.
125. Mayo, J.C.; Sainz, R.M.; Tan, D.X.; Hardeland, R.; Leon, J.; Rodriguez, C.; Reiter, R.J. Antiinflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol., 2005, 165, 139-149.
126. Mayo, J.C.; Tan, D.X.; Sainz, R.M.; Lopoz-Burillo, S.; Reiter, R.J. Oxidative damage to catalase induced by peroxy radicals: functional protection bymelatonin and other antioxidants. Free. Radic. Res., 2003, 37, 543-553.
127. Mctigue, D.M.; Tani, M.; Krivacic, K.; Chernosky, A.; Kelner, G.S.; Maciejewski, D.; Maki, R.; Ransohoff, R.M.; Stokes, B.T. Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J. Neurosci. Res., 1998, 53, 368-376.
128. Menendez-Pelaez, A.; Howes, K.A.; Gonzalez-Brito, A.; Reiter, R.J. N-acetyltransferase activity, hydroxyindole-Omethyltransferase activity, and melatonin levels in the Harderian glands of the female Syrian hamster: changes during the light:dark cycle and the effect of 6-parachlorophenylalanine administration. Biochem. Biophys. Res. Commun., 1987, 145, 1231-1238.
129. Minagar, A.; Shapshak, P.; Fujimura, R.; Ownby, R.; Heyes, M.; Eisdorfer, C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci., 2002, 202, 13-23.
130. Mohan, N.; Sadeghi, K.; Reiter, R.J.; Meltz, M.L. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem. Mol. Biol. Int., 1995, 37, 1063-1070.
131. Morera, A.L.; Abreu, P. Seasonality of psychopathology and circannual melatonin rhythm. J. Pineal Res., 2006, 41, 279-283.
132. Mott, J.D.; Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell. Biol., 2004, 16, 558-564.
133. Murphy, M.P. Nitric oxide and cell death. Biochim. Biophys. Acta., 1999, 1411, 401-414.
134. Nesic, O.; Lee, J.; Unabia, G.C.; Johnson, K.; Ye, Z.; Vergara, L.; Hulsebosch, C.E.; Perez-Polo, J.R. Aquaporin 1 - a novel player in spinal cord injury. J. Neurochem., 2008, 105, 628-640.
135. Nesic-Taylor, O.; Cittelly, D.; Ye, Z.; Xu, G.Y.; Unabia, G.; Lee, J.C.; Svrakic, N.M.; Liu, X.H.; Youle, R.J.; Wood, T.G.; McAdoo, D.; Westlund, K.N.; Hulsebosch, C.E.; Perez-Polo, J.R. Exogenous Bcl-xL fusion protein spares neurons after spinal cord injury. J. Neurosci. Res., 2005, 79, 628-637.
136. Noble, L.J.; Donovan, F.; Igarashi, T.; Goussev, S.; Werb, Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci., 2002, 22, 7526-7535.
137. Norrbrink Budh, C.; Hultling, C.; Lundeberg, T. Quality of sleep in individuals with spinal cord injury: a comparison between patients with and without pain. Spinal Cord., 2005, 43, 85-95.
138. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem., 2000, 275, 31311-31317.
139. Onuki, J.; Almeida, E.A.; Medeiros, M.H.; Di Mascio, P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J. Pineal. Res., 2005, 38, 107-115.
140. Ozcankaya, R.; Delibas, N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: Cross-sectional study. Croat. Med. J., 2002, 43, 28-32.
141. Pajovic, S.B.; Saicic, Z.S.; Spasic, M.B.; Petrovic, M.B. The effect of ovarian hormones on antioxidant enzyme activities in the brain of male rats. Physiol. Rev., 2003, 52, 189-194.
142. Paparrigopoulos, T.; Psarros, C.; Bergiannaki, J.; Varsou, E.; Dafni, U.; Stefanis, C. Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction. J. Affect. Disord., 2001, 65, 307-313.
143. Pappolla, M.A.; Chyan, Y.J.; Poeggeler, B.; Frangione, B.; Wilson, G.; Ghiso, J.; Reiter, R.J. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin. implications for Alzheimer's disease. J. Neural Transm., 2000, 107, 203-231.
144. Pappolla, M.A.; Simovich, M.J.; Bryant-Thomas, T.; Chyan, Y.J.; Poeggeler, B.; Dubocovich, M.; Bick, R.; Perry, G.; Cruz-Sanchez, F.; Smith, M.A. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J. Pineal Res., 2002, 32, 135-142.
145. Pappolla, M.A.; Sos, M.; Omar, R.A.; Bick, R.J.; Hickson-Bick, D.L.; Reiter, R.J.; Efthimiopoulos, S.; Robakis, N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci., 1997, 17, 1683-1690.
146. Peyrot, F.; Ducroig, C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J. Pineal Res., 2008, 45, 235-246.
147. Pieri, C.; Marra, M.; Moroni, F.; Recchioni, R.; Marcheselli, F. Melatonin: a peroxyl free radical scavenger more effective than vitamin E. Life Sci., 1994, 55, 271-276.
148. Pozo, D.; Reiter, R.J.; Calvo, J.R.; Guerrero, J.M. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J. Cell Biochem., 1997, 65, 430-442.
149. Ravindra, T.; Lakshmi, N.K.; Ahuja, Y.R. Melatonin in pathogenesis and therapy of cancer. Indian J. Med. Sci., 2006, 60, 523-535.
150. Rebrin, I.; Zicker, S.; Wedekind, K.J.; Paetau-Robinson, I.; Packer, L.; Sohal, R.S. Effect of antioxidant-enriched diets on glutathione redox status in tissue homogenates and mitochondria of the senescence-accelerated mouse. Free Radic. Biol. Med., 2005, 39, 549-557.
151. Reiter, R.J. Melatonin: the chemical expression of darkness. Mol. Cell. Endocrinol., 1991, 79, C153-C158.
152. Reiter, R.J. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J., 1995, 9, 526-533.
153. Reiter, R.J.; Acuna-Castroviejo, D.; Tan, D.X.; Burkhardt, S. Free radical-mediated molecular damage: mechanisms for the protective actions of melatonin in the central nervous system. Ann. N.Y. Acad. Sci., 2001, 939, 200-215.
154. Reiter, R.J.; Cabrera, J.; Sainz, R.M.; Mayo, J.C.; Manchester, L.C.; Tan, D.X. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. Ann. N.Y. Acad. Sci., 1999, 890, 471-485.
155. Reiter, R.J.; Tan, D.X.; Leon, J.; Kilic, U.; Kilic, E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp. Biol. Med., 2005, 230, 104-117.
156. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Tamura, H. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J. Physiol. Pharmacol., 2007, 58(Suppl. 6), 5-22.
157. Reiter, R.J.; Tan, D.X.; Qi, W.; Manchester, L.C.; Karbownik, M.; Calvo, J.R. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol. Signals Recept., 2000, 9, 160-171.
158. Reiter, R.J.; Tan, D.X.; Cabrera, J.; D'Arpa, D.; Sainz, R.M.; Mayo, J.C.; Ramos, S. The oxidant/antioxidant network: role of melatonin. Biol. Signals Recept., 1999, 8, 56-63.
159. Reiter, R.J.; Tan, D.X.; Jou, M.J.; Korkmaz, A.; Manchester, L.C.; Paredes, S.D. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro. Endocrinol. Lett., 2008, 29, 391-398.
160. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Pilar Terron, M.; Flores, L.J.; Koppisepi, S. Medical implications of melatonin: receptormediated and receptor independent actions. Adv. Med. Sci., 2007, 52, 11-28.
161. Reiter, RJ. Melatonin: clinical relevance. Best Pract. Res. Clin. Endocrinol. Metab., 2003, 17, 273-285.
162. Reppert, S.M. Melatonin receptors: molecular biology of a new family of G protein coupled receptors. J. Biol. Rhythms, 1997, 12(6), 528-531.
163. Reppert, S.M.; Perlow, M.J.; Tamarkin, L.; Klein, D.C. A diurnal melatonin rhythm in primate cerebrospinal fluid. Endocrinology, 1979, 104(2), 295-301
164. Ressmeyer, A.R.; Mayo, J.C.; Zelosko, V.; Sainz, R.M.; Tan, D.X.; Poeggeler, B.; Antolin, I.; Zsizsik, B.K.; Reiter, R.J.; Hardeland, R. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep., 2003, 8, 205-213.
165. Rodriguez, M.I.; Carretero, M.; Escames, G.; López, L.C.; Maldonado, M.D.; Tan, D.X.; Reiter, R.J.; Acuña-Castroviejo, D. Chronic melatonin treatment prevents age-dependent cardiac mitochondrial dysfunction in senescence-accelerated mice. Free Radic. Res., 2007, 41, 15-24.
166. Rodriguez, M.I.; Escames, G.; Lopez, L.C.; López, A.; García, J.A.; Ortiz, F.; Acuña-Castroviejo, D. Chronic melatonin treatment reduces the age-dependent inflammatory process in senescenceaccelerated mice. J. Pineal Res., 2007, 42, 272-279.
167. Rodriguez, M.I.; Escames, G.; Lopez, L.C.; Lopez, A.; Garcia, J.A.; Ortiz, F.; Sanchez, V.; Romeu, M.; Acuna-Castroviejo, D. Improved mitochondrial function and increased life span after chronic melatonin treatment in senescent prone mice. Exp. Gerontol., 2008, 43, 749-756.
168. Rosen, J.; Than, N.N.; Koch, D.; Poeggeler, B.; Laatsch, H.; Hardeland, R. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J. Pineal Res., 2006, 41, 374-381.
169. Rosenberg, G.A.; Dencoff, J.E.; Correa, N. Jr.; Reiners, M.; Ford, C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology, 1996, 46, 1626-1632.
170. Rosenberg, G.A.; Estrada, E.Y.; Denco, J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke., 1998, 29, 2189-2195.
171. Rosenbluth, J. Central myelin in the mouse mutant shiverer. J. Comp. Neurol., 1980, 194, 639-648.
172. Samantaray, S.; Sribnick, E.A.; Das, A.; Knaryan, V.H.; Matzelle, D.D.; Yallapragada, A.V.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J. Pineal. Res., 2008, 44, 348-357.
173. Sanchez-Hidalgo, M.; Lu, Z.; Tan, D.X. Melatonin inhibits fatty acid induced triglyceride accumulation in ROS 17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292, 2208-2215.
174. Sanchez-Moreno, C.; Dorfman, S.E.; Lichtenstein, A.H.; Martín, A. Dietary fat type affects vitamins C and E and biomarkers of oxidative status in peripheral and brain tissues of golden Syrian hamsters. J. Nutr., 2004, 134, 655-660.
175. Scheer, F.A.; Zeitzer, J.M.; Ayas, N.T.; Brown, R.; Czeisler, C.A.; Shea, S.A. Reduced sleep efficiency in cervical spinal cord injury; association with abolished night time melatonin secretion. Spinal Cord., 2006, 44, 78-81.
176. Seabra, M.L.; Bignotto, M.; Pinto, L.R. Jr; Tufik, S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res., 2000, 29, 193-200.
177. Sewerynek, E. Melatonin and the cardiovascular system. Neuro Endocrinol. Lett., 2002, 23, 79-83.
178. Shapiro, S.D. A concise yet informative stroll through matrix metalloproteinases and TIMPs. J. Cell. Sci., 2000, 113, 3355-3356.
179. Smirnov, A.N. Nuclear melatonin receptors. Biochemistry, 2001, 66(1), 19-26.
180. Southgate, G.; Daya, S. Melatonin reduces quinolinic acid-induced lipid peroxidation in rat brain homogenate. Metab. Brain Dis., 1999, 14, 165-171.
181. Soybir, G.; Topuzlu, C.; Odabas, O.; Dolay, K.; Bilir, A.; Köksoy, F. The effects of melatonin on angiogenesis and wound healing. Surg. Today, 2003, 33, 896-901.
182. Srinivasan, V.; Spence, D.W.; Trakh, I.; Pandi-Perumal, S.R.; Cardinali, D.P.; Maestroni, G.J. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation, 2008, 15, 93-101.
183. Steinhilber, D.; Brungs, M.; Werz, O.; Wiesenberg, I.; Danielsson, C.; Kahlen, J.P.; Nayeri, S.; Schrader, M.; Carlberg, C. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J. Biol. Chem., 1995, 270(13), 7037-7040.
184. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
185. Stover, S.L.; Fine, P.R. The epidemiology and economics of spinal cord injury. Paraplegia, 1987, 25, 225-228.
186. Sugden, D.; Davidson, K.; Hough, K.A.; The, M.T. Melatonin, melatonin receptors and melanophores: a moving story. Pigment Cell. Res., 2004, 17(5), 454-460.
187. Sun, F.Y.; Lin, X.; Mao, L.Z.; Ge, W.H.; Zhang, L.M.; Huang, Y.L.; Gu, J. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J. Pineal Res., 2002, 33, 48-56.
188. Swarnakar, S.; Mishra, A.; Ganguly, K.; Sharma, A.V. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J. Pineal Res., 2007, 43, 56-64.
189. Szczepanik, M. Melatonin and its influence on immune system. J. Physiol. Pharmacol., 2007, 58(6), 115-124.
190. Tan, D.X., Chen, L.D., Poeggeler, B. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr. J., 1993, 1, 57-60.
191. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Qi, W.B.; Karbownik, M.; Calvo, J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept., 2000, 9, 137-159.
192. Tan, D.X.; Manchester, L.C.; Hardeland, R.; Lopez-Burillo, S.; Mayo, J.C.; Sainz, R.M.; Reiter, R.J. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res., 2003, 34, 75-78.
193. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Qi, W.B.; Zhang, M.; Weintraub, S.T.; Cabrera, J.; Sainz, R.M.; Mayo, J.C. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim. Biophys. Acta., 1999, 1472, 206-214.
194. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Plummer, B.F.; Limson, J.; Weintraub, S.T.; Qi, W. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic. Biol. Med., 2000, 29, 1177-1185.
195. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Tamura, H.; Reiter, R.J. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J. Pineal Res. 2007, 43, 317-320.
196. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007, 42, 28-42.
197. Tan, D.X.; Reiter, R.J.; Manchester, L.C.; Yan, M.T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Kohen, R.; Allegra, M.; Hardeland, R. Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem.,2002, 2, 181-197.
198. Taskiran, D.; Tanyalcin, T.; Sozmen, E.Y.; Peker, G.O.; Gulmen, V.; Cagli, S.; Kanit, L.; Tekeli, G.; Barcin, E.; Zileli, M.; Kutay, F.Z. The effects of melatonin on the antioxidant systems in experimental spinal injury. Int. J. Neurosci., 2000, 104, 63-73.
199. Tator, C.H. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol., 1995, 5, 407-413.
200. Taupin, P. Adult neurogenesis, neuroinflammation and therapeutic potencial of adult neural i{dotless}tem cells. Int. J. Med. Sci., 2008, 5, 127-132.
201. Tjong, Y.W.; Li, M.F.; Hung, M.W.; Fung, M.L. Melatonin ameliorates hippocampal nitric oxide production and large conductance calcium-activated potassium channel activity in chronic intermittent hypoxia. J. Pineal Res., 2008, 44, 234-243.
202. Tomas-Zapico, C.; Coto-Montes, A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res., 2005, 39, 99-104.
203. Topsakal, C.; Kilic, N.; Ozveren, F.; Akdemir, I.; Kaplan, M.; Tiftikci, M.; Gursu, F. Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Spine, 2003, 28, 1643-1652.
204. Tu, Y.; Sun, R.Q.; Willis, W.D. Effects of intrathecal injections of melatonin analogs on capsaicin-induced secondary mechanical allodynia and hyperalgesia in rats. Pain, 2004, 109, 340-350.
205. Tunez, I.; Montilla, P.; Del Carmen Munoz, M.; Feijoo, M.; Salcedo, M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J. Pineal Res., 2004, 37, 252-256.
206. Tyor, W.R.; Avgeropoulos, N.; Ohlandt, G.; Hogan, E.L. Treatment of spinal cord impact injury in the rat with transforming growth factor beta. J. Neurol. Sci., 2002, 200, 33-41.
207. Vaillant, C.; Didier-Bazes, M.; Hutter, A.; Belin, M.F.; Thomasset, N. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J. Neurosci., 1999, 19, 4994-5004.
208. Vane, J.R.; Botting, R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 1998, 47, S78-S87.
209. Veneroso, C.; Tuñón, M.J.; González-Gallego, J.; Collado, P.S. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J. Pineal Res., 2009, 47(2), 184-91.
210. Wang, D.L.; Ling, Z.Q.; Cao, F.Y.; Zhu, L.Q.; Wang, J.Z. Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J. Pineal Res., 2004, 37, 11-16.
211. Wang, J.Z.; Wang, Z.F. Role of melatonin in Alzheimerlike neurodegeneration. Acta Pharmacol. Sin., 2006, 27, 41-49.
212. Wang, X., Figueroa, B.E., Stavrovskaya, I.G., Zhang, Y., Zhu, S., Day, A.L., Kristal, B.S., Friedlander, R.M. Methazolamide and melatonin inhibit mitochondrial cytochrome c release and are neuroprotective in experimental models of ischemic injury. Stroke, 2009, 40, 1877-1885.
213. Wang, X.C., Zhang, J., Yu, X., Han, L., Zhou, Z.T., Zhang, Y., Wang, J.Z. Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Sheng Li Xue Bao., 2005, 57, 7-12.
214. Weishaupt, J.H.; Bartels, C.; Polking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S.; Bohn, M.; Huther, G.; Schneider, A.; Bach, A.; Sirén, A.L.; Hardeland, R.; Bähr, M.; Nave, K.A.; Ehrenreich, H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res., 2006, 41, 313-323.
215. Wells, J.E.; Rice, T.K.; Nuttall, R.K.; Edwards, D.R.; Zekki, H.; Rivest, S.; Yong V.W. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J. Neurosci., 2003, 23, 10107-10115.
216. Witt-Enderby, P.A.; Bennett, J.; Jarzynaka, M.M.; Firestine, S.; Melan, M.A. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci., 2003, 72, 2183-2198.
217. Xiong, Y.; Rabchevsky, A.G.; Hall, E.D. Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J. Neurochem., 2007, 100, 639-649.
218. Xu, Z.; Wang, B.R.; Wang, X.; Kuang, F.; Duan, X.L.; Jiao, X.Y.; Ju, G. Erk1/2 and p38 mitogen activated protein kinase mediate inos-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sci., 2006, 79, 1895-1905.
219. Yeung, H.M., Hung, M.W., Fung, M.L. Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. J. Pineal Res., 2008, 45, 373-382.
220. Yong, V.W.; Power, C.; Forsyth, P.; Edwards, D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci., 2001, 2, 502-511.
221. Yun, H.Y., Dawson, V.L., Dawson, T.M. Nitric oxide in health and diseases of the nervous system. Mol. Psychiatry, 1997, 2, 300-310.
222. Yune, T.Y., Chang, M.J., Kim, S.J.; Lee, Y.B.; Shin, S.W.; Rhim, H.; Kim, Y.C.; Shin, M.L.; Oh, Y.J.; Han, C.T.; Markelonis, G.J., Oh, T.H. Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats. J. Neurotrauma., 2003, 20, 207-219.
223. Zeitzer, J.M., Ayas, N.T., Shea, S.A. Brown, R.; Czeisler, C.A. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J. Clin. Endocrinol. Metab., 2000, 85, 2189-2196.
224. Zeitzer, J.M., Ayas, N.T., Wu, A.D.; Czeisler, C.A.; Brown, R. Bilateral oculosympathetic paresis associated with loss of nocturnal melatonin secretion in patients with spinal cord injury. J. Spinal Cord. Med., 2005, 28, 55-59.
225. Zhou, J., Zhang, S., Zhao, X., Wei, T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J. Pineal Res., 2008, 45, 157-165.